Vericel Corp (VCEL) : Stonepine Capital Management scooped up 832,061 additional shares in Vericel Corp during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 10, 2016. The investment management firm now holds a total of 2,250,000 shares of Vericel Corp which is valued at $4,882,500.Vericel Corp makes up approximately 5.21% of Stonepine Capital Management’s portfolio.
Other Hedge Funds, Including , Acrospire Investment Management added VCEL to its portfolio by purchasing 21,430 company shares during the most recent quarter which is valued at $48,860. Vericel Corp makes up approx 0.04% of Acrospire Investment Management’s portfolio. Alambic Investment Management added VCEL to its portfolio by purchasing 37,285 company shares during the most recent quarter which is valued at $79,790. Vericel Corp makes up approx 0.02% of Alambic Investment Management’s portfolio.Perkins Capital Management Inc reduced its stake in VCEL by selling 25,750 shares or 10.04% in the most recent quarter. The Hedge Fund company now holds 230,750 shares of VCEL which is valued at $493,805. Vericel Corp makes up approx 0.54% of Perkins Capital Management Inc’s portfolio. Acadian Asset Management added VCEL to its portfolio by purchasing 5,617 company shares during the most recent quarter which is valued at $11,964.
Vericel Corp opened for trading at $2.21 and hit $2.36 on the upside on Friday, eventually ending the session at $2.25, with a gain of 2.74% or 0.06 points. The heightened volatility saw the trading volume jump to 3,82,116 shares. Company has a market cap of $54 M.
Vericel Corporation (Vericel) formerly Aastrom Biosciences Inc. develops patient-specific expanded cellular therapies for use in the treatment of patients with diseases and conditions. Vericel markets two autologous cell therapy products in the United States: Carticel (autologous cultured chondrocytes) an autologous chondrocyte implant for the treatment of cartilage defects in the knee and Epicel (cultured epidermal autografts) a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns greater than or equal to 30% of total body surface area (TBSA). The Company is also developing ixmyelocel-T a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. The Company has two cell manufacturing facilities in Cambridge Massachusetts and Copenhagen Denmark. Vericel also operates a centralized cell manufacturing facility in Ann Arbor Michigan.
News 
Market Data 
Discover 
